CLINICAL_TRIALS
trial_result
· 2008-03-03
Clinical Trial Update: Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly [Phase 4]
Summary
Phase 4 clinical trial update indicates Lanreotide Autogel 120 mg was studied as first-line therapy for acromegaly; the trial status is completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Federico II University | Conditions: Acromegaly | Phase 4 | Status: COMPLETED